NVO Stock Price Today (April 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-04-15
Novo Nordisk A/S (NVO) is trading at $40.93, up 4.09% today (as of April 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $47.12 (15.1% upside).
- Volatility remains elevated (21.56% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-7.60% YoY) alongside significant competitive pressures.
NVO Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $268.34B
P/E Ratio
Forward P/E: 10.81
Revenue Growth
Year over Year
Analyst Target
+15.1% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a overbought technical setup with challenging fundamentals.
- Technicals say: Overbought (RSI 74.86)
- Fundamentals say: Challenging (declining revenue trends)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $130.96B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $81.44—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.56% annualized volatility and β=0.27, the stock exhibits low sensitivity to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Kailera nets $625M in one of biotech’s biggest-ever IPOs
The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.
Hims & Hers Spikes; Will The FDA Blow The Door Open On Peptide Compounding?
Hims stock jumped Thursday after the FDA said its advisors would weigh in on whether compounding pharmacies can make specific peptides.
Novo Workforce Changes May Signal Ongoing Reset
Hiring continues as company adjusts staffing
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
There are other factors to consider before investing in this -- or any other -- healthcare company.
Novo Nordisk Expands Workforce After Deep Cuts
Hiring rebound signals ongoing restructuring and demand strength
Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides
Hims & Hers stock jumped as RFK Jr. signaled that the FDA may ease restrictions on peptides.
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
LLY stock slips after FDA seeks added safety data on its new oral obesity pill Foundayo, raising questions despite blockbuster sales hopes.
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
Eli Lilly's Q1 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
Indian's Hetero targets annual sales of 1.5 million semaglutide pens in global rollout
By Rishika Sadam HYDERABAD, April 16 (Reuters) - Hetero Labs, one of India's largest privately held drugmakers, aims to sell 1.5 million pens of generic weight-loss and diabetes drugs in the first
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $40.93. The RSI (14-day) is at 74.9, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $47.12 implies 15.1% upside from current levels. Volatility is moderate at 21.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 10.39, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 10.81. The PEG ratio is 4.89, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.47. Price-to-Sales is 0.53. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $47.12. This represents a 15.1% upside from the current price of $40.93. The range spans from a low target of $39.85 to a high target of $63.60, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 4.40%. The annualized dividend rate is $11.70 per share. The payout ratio is 50.4%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-03-30.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Declining revenue (-7.6% YoY), indicating potential business headwinds. 2. Elevated short interest (77.0% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $130.96B. The debt-to-equity ratio is 67.49, which is moderate and generally manageable for most companies. The current ratio is 0.80, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.54. The company holds $26.96B in cash and equivalents. Free cash flow is positive at $376.88M, providing a cushion for debt servicing and shareholder returns.